Answers are grounded in this paper and cite their sources.
Recent advances in cystic fibrosis (CF) treatment, particularly the development of CFTR modulators (CFTRm), have transformed disease management and substantially improved survival, health status, and reproductive outcomes in people with CF. In addition to lung symptoms, CF is characterised by pancreatic insufficiency, meconium ileus, and reduced fertility, leading to a shorter life expectancy. CFTRm, e.g. elexacaftor-tezacaftor-ivacaftor partially restore CFTR function. Together, these treatments have markedly improved survival and quality of life for individuals with CF. As increasing numbers of women with CF conceive while taking CFTRm, understanding maternal-fetal drug exposure has become a clinical priority. Emerging evidence demonstrates that CFTRm cross the placenta and can be detected in cord blood, neonatal plasma, and infant tissues. However, the extent of fetal exposure, tissue accumulation and potential developmental implications remain incompletely understood. Herein, we emphasise the mechanistic and pharmacological evidence underlying fetal exposure to CFTRm . This review synthesises current evidence regarding the transplacental transfer, fetal exposure and developmental implications of CFTRm during pregnancy. We discuss emerging pharmacokinetic data, reported maternal and infant outcomes and key knowledge gaps that remain regarding the safety of in utero CFTRm exposure.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: